Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Locally Advanced Pancreatic Adenocarcinoma: early-phase trial registry
11 of 19 indexed Locally Advanced Pancreatic Adenocarcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 11 currently recruiting · #902 of 28,707 conditions by registered trial count
Locally Advanced Pancreatic Adenocarcinoma: 19 US clinical trials tracked, 11 recruiting.
Locally Advanced Pancreatic Adenocarcinoma is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 15 in Phase 1-2 (earlier-stage). The most active sponsor is National Cancer Institute (NCI), running 3 of these trials.
Enrollment posture brief
Registry condition locally-advanced-pancreatic-adenocarcinoma
OPEN 11 | RECR 58% | LATE 2 | EARLY 15 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Burnout (58% recruiting · 19 trials)
Locally Advanced Pancreatic Adenocarcinoma lists 11 open slots (58% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Locally Advanced Pancreatic Adenocarcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Locally Advanced Pancreatic Adenocarcinoma is recruiting above its size-band peers.
11 of 19 indexed trials (57.9%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Locally Advanced Pancreatic Adenocarcinoma research.
National Cancer Institute (NCI) accounts for 3 of 19 trials (15.8%). 17 distinct sponsors appear on at least one study for this condition label.
-
Most Locally Advanced Pancreatic Adenocarcinoma trials plan to enrol fewer than 100 people.
Median target enrolment is 30 among the 19 trials that report a genuine target (sentinel values excluded). 18 of those (94.7%) plan for fewer than 100 participants.
-
Locally Advanced Pancreatic Adenocarcinoma research is mostly interventional.
19 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer
Quercis Pharma
NCT06861088
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
NCT06998940
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer
National Cancer Institute (NCI)
NCT04172532
Neoadjuvant Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma
Wake Forest University Health Sciences
NCT05825066
Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Medical University of South Carolina
NCT07076212
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
Baptist Health South Florida
NCT05679674
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
Xerient Pharma
NCT07157033
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
University of California, Davis
NCT04665947
PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC)
PanTher Therapeutics
NCT06673017
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advanced or Metastatic Pancreatic Cancer
Mayo Clinic
NCT06381154
Acoustic Cluster Therapy (ACT) With Chemotherapy for the Treatment of Locally Advanced Pancreatic Cancer
EXACT Therapeutics AS
NCT06850623
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
National Cancer Institute (NCI)
NCT01585805
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
TriSalus Life Sciences
NCT05607953
BATs Treatment for Pancreatic Cancer, Phase Ib/II
University of Virginia
NCT03269526
Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer
HonorHealth Research Institute
NCT04669197
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
National Cancer Institute (NCI)
NCT00669734
Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
OHSU Knight Cancer Institute
NCT05034627
PROACTIVE: Surgical Resection Outcomes in Locally Advanced and Unresectable Pancreatic Cancer After Neoadjuvant Chemotherapy
University of Southern California
NCT06132087
Immunochemoradiotherapy in Patients With Pancreatic Cancer
Providence Health & Services
NCT01342224
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 6 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Locally Advanced Pancreatic Adenocarcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Locally Advanced Pancreatic Adenocarcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Locally Advanced Pancreatic Adenocarcinoma page
19 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Locally Advanced Pancreatic Adenocarcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- National Cancer Institute (NCI) sponsors the most Locally Advanced Pancreatic Adenocarcinoma trials on record, review their full trial history before evaluating a specific study. See National Cancer Institute (NCI)'s trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Locally Advanced Pancreatic Adenocarcinoma condition card totals 19 registered trials; most-linked intervention Computed Tomography; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.